In MPN, inhibition of BRAF or MEK has been explored in combination with JAK2 inhibitors in vitro [13–15] and RAS/MAPK pathway gene mutations were shown to impact on response to treatment and outcome of MPN patients [16, 17]. Here, MAP2K7 is linked to myeloproliferative disorder.